LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 67

Search options

  1. Article ; Online: 'Contribution of component' and the perioperative immune-checkpoint inhibitor precedent.

    Strohbehn, Garth W / Gyawali, Bishal

    Nature reviews. Clinical oncology

    2024  Volume 21, Issue 4, Page(s) 249–250

    MeSH term(s) Humans ; Immune Checkpoint Inhibitors
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-023-00857-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.

    Strohbehn, Garth W / Ratain, Mark J

    Nature reviews. Clinical oncology

    2024  Volume 21, Issue 5, Page(s) 331–332

    MeSH term(s) Humans ; Cost-Benefit Analysis ; Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use ; Drug Costs
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2024-04-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-024-00862-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Special designations and the US Food and Drug Administration's "dual mandate".

    Strohbehn, Garth W / Ratain, Mark J

    Journal of the National Cancer Institute

    2024  Volume 116, Issue 2, Page(s) 177–179

    MeSH term(s) United States ; Humans ; Pharmaceutical Preparations ; United States Food and Drug Administration ; Antineoplastic Agents ; Neoplasms/drug therapy
    Chemical Substances Pharmaceutical Preparations ; Antineoplastic Agents
    Language English
    Publishing date 2024-01-24
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djad235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: New strategies for dose optimization in oncology: insights from targeted small-molecule therapies for metastatic or advanced non-small cell lung cancer.

    Strohbehn, Garth W

    Clinical advances in hematology & oncology : H&O

    2022  Volume 21, Issue 4, Page(s) 205–208

    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/therapy ; Antineoplastic Agents/therapeutic use ; Medical Oncology ; Molecular Targeted Therapy
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2022-10-25
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation?

    Gyawali, Bishal / Strohbehn, Garth W

    JAMA oncology

    2023  Volume 10, Issue 1, Page(s) 41–42

    MeSH term(s) Humans ; Cell Transformation, Neoplastic ; Immunotherapy
    Language English
    Publishing date 2023-11-16
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.4799
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Precision and Accuracy in the Brave New World of Basket Trials.

    Strohbehn, Garth W / Ratain, Mark J

    JCO precision oncology

    2022  Volume 3, Page(s) 1–5

    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.19.00074
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

    Ratain, Mark J / Strohbehn, Garth W

    European journal of cancer (Oxford, England : 1990)

    2023  Volume 194, Page(s) 113349

    Abstract: Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration's Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised ... ...

    Abstract Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration's Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers as well as patients and physicians in low- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective and can be delivered at lower doses, resulting in less toxicity for patients, and lower costs for patients and payers. We illustrate this opportunity by discussing the combination of atezolizumab and bevacizumab, approved in multiple countries for both non-small cell lung cancer and hepatocellular cancer. Our conclusion is that the cost of this regimen can be reduced by more than 80%, an opportunity that should be considered by patients, prescribers, payers, and policymakers.
    MeSH term(s) Humans ; Bevacizumab/adverse effects ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2023-09-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/j.ejca.2023.113349
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

    Strohbehn, Garth W / Lichter, Allen S / Ratain, Mark J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 14, Page(s) 2488–2492

    MeSH term(s) Humans ; Neoplasms/drug therapy ; Government
    Language English
    Publishing date 2023-02-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.02049
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Lorlatinib Exposed: A Far From Optimal Dose.

    Strohbehn, Garth W / Ratain, Mark J

    Clinical pharmacology and therapeutics

    2022  Volume 111, Issue 6, Page(s) 1195–1196

    MeSH term(s) Aminopyridines/adverse effects ; Carcinoma, Non-Small-Cell Lung ; Humans ; Lactams ; Lactams, Macrocyclic ; Lung Neoplasms ; Protein Kinase Inhibitors/adverse effects ; Pyrazoles/adverse effects
    Chemical Substances Aminopyridines ; Lactams ; Lactams, Macrocyclic ; Protein Kinase Inhibitors ; Pyrazoles ; lorlatinib (OSP71S83EU)
    Language English
    Publishing date 2022-04-08
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.2579
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Targeted randomization dose optimization trials enable fractional dosing of scarce drugs

    Philip S. Boonstra / Alex Tabarrok / Garth W. Strohbehn

    PLoS ONE, Vol 18, Iss

    2023  Volume 10

    Keywords Medicine ; R ; Science ; Q
    Language English
    Publishing date 2023-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top